Advair

Advair

(ăd′vâr′)
A trademark for drug combination of fluticasone propionate and salmeterol.

Advair™

A proprietary inhalation product for treating asthma which combines salmeterol xinafoate—Serevent®, a long-acting bronchodilator—with fluticasone propionate—Flovent®, an inhaled corticosteroid anti-inflammatory—in a single breath-activated Diskus inhaler device.
Mentioned in ?
References in periodicals archive ?
The strong performance helped to offset lower growth in its pharmaceuticals section after a rival firm got the green light to make a version of its profitable asthma drug Advair.
Emma Walmsley, CEO, GSK said: "GSK delivered continued good operating performance in Q2 despite the loss of exclusivity of Advair. We are increasing our expectations for the year and have updated our guidance for 2019.
Wixela, a generic form of GlaxoSmithKlinePLC's Advair drug for chronic obstructive pulmonary disease, is expected to deliver "modest" revenue growth in the near-term.
PITTSBURGH -- Mylan NV late last month won Food and Drug Administration approval of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the first generic version of GlaxoSmithKline PLC's Advair Diskus.
PHARMACEUTICAL giant Glaxo-SmithKline has posted rising sales but warned its profitability will take a hit due to competition against its asthma drug Advair.
The company added the Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP) is the first generic version of ADVAIR DISKUS.
The products that will no longer carry this boxed warning in their labels include AstraZeneca's budesonide/formoterol fumarate dihydrate (Symbicort) and GlaxoSmithKline's fluticasone furoate/vilanterol (Breo Ellipta) and fluticasone propionate/salmeterol (Advair Diskus and Advair HFA).
Hikma is currently also in a dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the US.
* Advair (fluticasone propionate/salmeterol; GSK): Advair and Symbicort have similar NPS scores.
Some big-selling products, like the respiratory medicine Advair and the diabetes drug Victoza, have suffered precipitous declines in market share because Express Scripts, the biggest pharmacy benefits manager, recently stopped paying for them for many patients.
The respiratory franchise grew 6% to [pounds sterling]1.9 billion, with Advair sales of [pounds sterling]1.3 billion (+4%) and Flovent sales +7% to [pounds sterling]213 million.